Condition (MeSH)
Ganglioglioma
ClinicalTrials.gov lists 12 trials for Ganglioglioma or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Ganglioglioma itself; the rest are tagged with a narrower condition beneath it.
When did Ganglioglioma trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2021 | 1 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 2 |
| 2013 | 1 |
| 2011 | 1 |
| 1996 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ganglioglioma trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 4 |
How many Ganglioglioma trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Active, not recruiting | 3 |
| Completed | 6 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ganglioglioma trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 2 |
Which drugs are being tested for Ganglioglioma? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| GSK1120212 | 2 |
| Dabrafenib | 2 |
| Irinotecan | 1 |
| Mirdametinib | 1 |
| Cytoxan | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 1 |
| rQNestin | 1 |
| Vincristina | 1 |
| Antineoplaston therapy (Atengenal + Astugenal) | 1 |
| Bevacizumab 1 | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Ganglioglioma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pyrexia | 23 | 1 |
| Somnolence/depressed level of consciousness | 9 | 1 |
| Seizure | 8 | 2 |
| Headache | 6 | 1 |
| Hydrocephalus | 5 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Ganglioglioma? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entity. | Brain pathology (Zurich, Switzerland) | 2019 | Yes |
| Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. | Journal of the National Comprehensive Cancer Network : JNCCN | 2016 | Yes |
| Radiation tolerance limits of the brainstem. | Neurosurgery | 2008 | Yes |
| Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. | Neuropathology and applied neurobiology | 2001 | Yes |
| Low grade glial neoplasms. | Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia | 2003 | No |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Ganglioglioma | 251949 | Exact | Orphadata Science knowledge files, Product 1 |
| Ganglioglioma | 251949 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and sub-conditions in mesh.